Drug safety evaluation / Shayne Cox Gad, Dexter W. Sullivan Jr.

By: Gad, Shayne C, 1948- [author.]
Contributor(s): Sullivan, Dexter W., Jr [author.]
Language: English Publisher: Hoboken, NJ : Wiley, 2023Edition: 4th editionDescription: 1 online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9781119755852 ; 9781119755876 ; 9781119755869Subject(s): Drug Evaluation, Preclinical | Drug Evaluation | Product Surveillance, PostmarketingGenre/Form: DDC classification: 615/.19 LOC classification: RA1238Online resources: Full text available at Wiley Online Library Click here to view.
Contents:
Table of Contents PREFACE xxix ABOUT THE AUTHORS xxxi 1 The Drug Development Process and The Global Pharmaceutical Marketplace 1 2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market 19 3 Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation 67 4 Electronic Records, Reporting, and Submission: eCTD and Send 75 5 Screens in Safety and Hazard Assessment 83 6 Formulations, Routes, and Dosage Regimens 95 7 Mechanisms And End Points Of Drug Toxicity 131 8 Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF 143 9 Repeat-Dose Toxicity Studies 173 10 Genotoxicity 183 11 QSAR Tools For Drug Safety 223 12 Toxicogenomics 241 13 Immunotoxicology In Drug Development 247 14 Nonrodent Animal Studies 293 15 Developmental And Reproductive Toxicity Testing 331 16 Carcinogenicity Studies 363 17 Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment 395 18 Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment 403 19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation 425 20 Safety Pharmacology 457 21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products 477 22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs 507 23 Special Case Products: Imaging Agents 529 24 Special Case Products: Drugs For Treatment Of Cancer 535 25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology) 543 26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology 551 27 Occupational Toxicology In The Pharmaceutical Industry 571 28 Strategy and Phasing For Nonclinical Drug Safety EvaluationIn The Discovery and Development of Pharmaceuticals 585 29 The Application of In Vitro Techniques In Drug Safety Assessment 603 30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond 635 31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs) 683 32 Statistics In Pharmaceutical Safety Assessment 707 33 Combination Products: Drugs and Devices 767 34 Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals 777 35 Tissue, Cell, and Gene Therapy 789 36 Adverse Outcome Pathways in Drug Safety Assessment 801 Appendix A: Selected Regulatory and Toxicological Acronyms 805 Appendix B: Definition Of Terms And Lexicon of "Clinical" Observations in Nonclinical (Animal) Studies 807 Appendix C: Notable Regulatory Internet Addresses 811 Appendix D: Glossary Of Terms Used in The Clinical Evaluation of Therapeutic Agents 817 Appendix E: Common Vehicles For The Nonclinical Evaluation of Therapeutic Agents 821 Appendix F: Global Directory of Contract Toxicology Labs 919 INDEX 945
Summary: "This new edition of Drug Safety Evaluation presents an all-inclusive practical guide for those who are responsible for developing new drugs and ensuring the safety of an ever-expanding spectrum of therapeutics. This book helps readers understand how the safety of these products are evaluated for use. Extensively revised to reflect up-to-date information, this edition includes changes to the scope of products (vaccines, small synthetic, large protein moieties, cells and tissues), harmonized global and national regulatory requirements, the therapeutic development process, and available technologies to identify and evaluate the relevance of potential patient risks. The revised chapter, and inclusion of brand-new chapters, address specific approaches to evaluating hazards, including problems that are encountered and their solutions. Also covered are the scientific and philosophical bases for evaluation of specific concerns (including carcinogenicity, developmental toxicity, immunogenicity and immunotoxicity) to provide both understanding and guidance for approaching new problems"-- Provided by publisher.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
Item type Current location Home library Call number Status Date due Barcode Item holds
EBOOK EBOOK COLLEGE LIBRARY
COLLEGE LIBRARY
615.19 G116 2023 (Browse shelf) Available CL-51291
Total holds: 0

Includes bibliographical references and index.

Table of Contents
PREFACE xxix

ABOUT THE AUTHORS xxxi

1 The Drug Development Process and The Global Pharmaceutical Marketplace 1

2 Regulation of Human Pharmaceutical Safety: Routes To Human Use and Market 19

3 Data Mining: Sources of Information For Consideration In Study And Program Design and In Safety Evaluation 67

4 Electronic Records, Reporting, and Submission: eCTD and Send 75

5 Screens in Safety and Hazard Assessment 83

6 Formulations, Routes, and Dosage Regimens 95

7 Mechanisms And End Points Of Drug Toxicity 131

8 Pilot Toxicity Testing In Drug Safety Evaluation: MTD and DRF 143

9 Repeat-Dose Toxicity Studies 173

10 Genotoxicity 183

11 QSAR Tools For Drug Safety 223

12 Toxicogenomics 241

13 Immunotoxicology In Drug Development 247

14 Nonrodent Animal Studies 293

15 Developmental And Reproductive Toxicity Testing 331

16 Carcinogenicity Studies 363

17 Histopathology and Clinical Pathology In Nonclinical Pharmaceutical Safety Assessment 395

18 Irritation And Local Tissue Tolerance In Pharmaceutical Safety Assessment 403

19 Pharmacokinetics And Toxicokinetics In Drug Safety Evaluation 425

20 Safety Pharmacology 457

21 Special Concerns For The Preclinical Evaluation Of Biotechnology Products 477

22 Safety Assessment of Inhalant Drugs And Dermal Route Drugs 507

23 Special Case Products: Imaging Agents 529

24 Special Case Products: Drugs For Treatment Of Cancer 535

25 Pediatric Product Safety Assessment (2006 Guidance, Including Juvenile And Pediatric Toxicology) 543

26 Use Of Imaging, Imaging Agents, And Radiopharmaceuticals In Nonclinical Toxicology 551

27 Occupational Toxicology In The Pharmaceutical Industry 571

28 Strategy and Phasing For Nonclinical Drug Safety EvaluationIn The Discovery and Development of Pharmaceuticals 585

29 The Application of In Vitro Techniques In Drug Safety Assessment 603

30 Evaluation Of Human Tolerance And Safety In Clinical Trials: Phase I And Beyond 635

31 Postmarketing Safety Evaluation: Monitoring, Assessing, And Reporting of Adverse Drug Responses (ADRs) 683

32 Statistics In Pharmaceutical Safety Assessment 707

33 Combination Products: Drugs and Devices 767

34 Qualification Of Impurities, Degradants, Residual Solvents, Metals, and Leachables in Pharmaceuticals 777

35 Tissue, Cell, and Gene Therapy 789

36 Adverse Outcome Pathways in Drug Safety Assessment 801

Appendix A: Selected Regulatory and Toxicological Acronyms 805

Appendix B: Definition Of Terms And Lexicon of "Clinical" Observations in Nonclinical (Animal) Studies 807

Appendix C: Notable Regulatory Internet Addresses 811

Appendix D: Glossary Of Terms Used in The Clinical Evaluation of Therapeutic Agents 817

Appendix E: Common Vehicles For The Nonclinical Evaluation of Therapeutic Agents 821

Appendix F: Global Directory of Contract Toxicology Labs 919

INDEX 945

"This new edition of Drug Safety Evaluation presents an all-inclusive practical guide for those who are responsible for developing new drugs and ensuring the safety of an ever-expanding spectrum of therapeutics. This book helps readers understand how the safety of these products are evaluated for use. Extensively revised to reflect up-to-date information, this edition includes changes to the scope of products (vaccines, small synthetic, large protein moieties, cells and tissues), harmonized global and national regulatory requirements, the therapeutic development process, and available technologies to identify and evaluate the relevance of potential patient risks. The revised chapter, and inclusion of brand-new chapters, address specific approaches to evaluating hazards, including problems that are encountered and their solutions. Also covered are the scientific and philosophical bases for evaluation of specific concerns (including carcinogenicity, developmental toxicity, immunogenicity and immunotoxicity) to provide both understanding and guidance for approaching new problems"-- Provided by publisher.

About the Author
Shayne Cox Gad, PhD, DABT is the Principal of Gad Consulting Services. He has more than 47 years of experience as a toxicologist, statistical consultant, manager, and consultant on research and development in the chemical, consumer product, contract testing, biotechnology, medical device, and pharmaceutical industries. He has successfully file 138 INDs and authored and edited 52 books, as well as numerous papers, presentations, and other publications.

Dexter W. Sullivan, Jr., MS, DABT is Senior Toxicologist at Gad Consulting Services.

Description based on print version record and CIP data provided by publisher; resource not viewed.

There are no comments for this item.

to post a comment.